Valeant Pharma (VRX) Reports Q1 Adjusted EBITDA of $861M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Valeant Pharma (VRX) Outperforms Amid Broad Weakness
May 11, 2017 9:54 AM EDTValeant Pharma (NYSE: VRX) Outperforms Amid Broad Weakness
... MoreStifel Comments On Valeant (VRX) Earnings
May 9, 2017 10:25 AM EDTStifel maintains Buy on Valeant Pharmaceuticals (NYSE: VRX) price target of $45.00.
Analyst Annabel Samimy stands out as one of two sell-side analysts who is bullish on the name with a Buy rating. Samimy expects headwinds to persist through the end of 2017 from managed... More
